Guotai CSI BIOMEDICINE ETF(512290) rises 2.63%, with the latest scale reaching 3.821 billion yuan

NewTimeSpace (newtimespace.com) News, as of 14:37 on July 3, 2026, Guotai Biopharmaceutical ETF (512290) rose 2.63%, with the latest price at 1.01 yuan. Over a longer time frame, as of July 2, 2026, the ETF accumulated a gain of 6.93% over the past week.

In terms of liquidity, Guotai Biopharmaceutical ETF recorded an intraday turnover rate of 6.32% and a trading volume of 244 million yuan. Over a longer time frame, as of July 2, the ETF's average daily trading volume over the past week reached 234 million yuan.

In terms of scale, the latest scale of Guotai Biopharmaceutical ETF reached 3.821 billion yuan. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. The net margin financing purchase amount of Guotai Biopharmaceutical ETF on the previous trading day reached 2.4707 million yuan, with the latest margin financing balance standing at 149 million yuan. (Data source: Wind)

As of July 2, the net value of Guotai Biopharmaceutical ETF rose by 17.31% over the past two years. From the perspective of return capability, as of July 2, 2026, since its inception, the ETF achieved a highest single-month return of 23.26%, a longest streak of consecutive up months of 8 months, a maximum cumulative gain during that streak of 109.28%, and an average return of 6.39% in up months. As of July 2, 2026, the ETF's annualized excess return over its benchmark for the past three months was 3.79%.

In terms of drawdown, as of July 2, 2026, Guotai Biopharmaceutical ETF recorded a drawdown of 0.11% relative to its benchmark since the beginning of the year.

In terms of fees, Guotai Biopharmaceutical ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%.

In terms of tracking accuracy, as of July 2, 2026, the one-year tracking error of Guotai Biopharmaceutical ETF was 0.031%.

Guotai Biopharmaceutical ETF closely tracks the CSI Biopharmaceutical Index. The CSI Biopharmaceutical Index selects the securities of listed companies that provide products and services in cell therapy, gene sequencing, blood products, biotechnology drugs, vaccines, in vitro diagnostics, and related fields as index constituents, in order to reflect the overall performance of biopharmaceutical listed company securities.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.